Enter your email address
Submit
Write your message
Fri, May 3, 2024
[Archive]
Volume 3, Issue 3 (Summer 2018)
J Obstet Gynecol Cancer Res 2018, 3(3): 123-128 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Aminimoghaddam S, Abolghasem N, Ashraf- Ganjooie T. New Management of Gestational trophoblastic
diseases; A Continuum of Moles to Choriocarcinoma:
A Review Article. J Obstet Gynecol Cancer Res 2018; 3 (3) :123-128
URL: http://jogcr.ir/article-1-211-en.html
URL: http://jogcr.ir/article-1-211-en.html
1- Obstetrics & Gynecology Department, Medical Faculty, Iran University of Medical Sciences, Tehran, Iran
2- Obstetrics & Gynecology Department, Medical Faculty, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2- Obstetrics & Gynecology Department, Medical Faculty, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Abstract: (2415 Views)
Introduction: Gestational trophoblastic diseases (GTD) is the only group of female reproductive neoplasms derived from paternal genetic material (Androgenic origin). GTD is a continuum from benign to malignant; molar pregnancy is benign, but choriocarcinoma is malignant. Approximately 45% of patients have metastatic disease when Gestational trophoblastic neoplasia (GTN) is diagnosed. GTN is unique in women malignancies because it arises from trophoblast but not from genital organs. It is curable with chemotherapy, low-risk GTN completely response to single-agent chemotherapy and does not require histological confirmation. In persistent GTN, clinical staging and workup of metastasis should be performed. The aim of the present study was to review the new management of GTD.
Conclusion In the case of brain, liver, or renal metastases, any woman of reproductive age who presents with an apparent metastatic malignancy of unknown primary site should be screened for the possibility of GTN with a serum HCG level. Excisional biopsy is not indicated to histologically confirm the diagnosis of malignant GTN if the patient is not pregnant and has a high HCG value. Given the vascular nature of these lesions, a biopsy can have significant morbidity. In every woman with abnormal bleeding or neurologic symptom without documented reason, the probability of malignant GTN should be in mind and determination of HCG titer is recommended. In selected cases with low-risk GTN, repeat curettage is done to reduce the need for chemotherapy courses. In recent years personalized medicine is encouraged for treatment of GTN.
Conclusion In the case of brain, liver, or renal metastases, any woman of reproductive age who presents with an apparent metastatic malignancy of unknown primary site should be screened for the possibility of GTN with a serum HCG level. Excisional biopsy is not indicated to histologically confirm the diagnosis of malignant GTN if the patient is not pregnant and has a high HCG value. Given the vascular nature of these lesions, a biopsy can have significant morbidity. In every woman with abnormal bleeding or neurologic symptom without documented reason, the probability of malignant GTN should be in mind and determination of HCG titer is recommended. In selected cases with low-risk GTN, repeat curettage is done to reduce the need for chemotherapy courses. In recent years personalized medicine is encouraged for treatment of GTN.
Systematic Review: Review |
Subject:
Obstetrics and Gynecology
Received: 2018/03/13 | Accepted: 2018/04/29 | Published: 2018/09/22
Received: 2018/03/13 | Accepted: 2018/04/29 | Published: 2018/09/22
References
1. Aminimoghaddam S, Maghsoudnia A. Unusual presentation of invasive mole: A case report. J Reprod Infertil. 2017;18(1):205-9.
2. Aminimoghaddam S. A review of recent findings for obstetricians about combined oral contraceptive pills. J Obstet Gynecol Cancer Res. 2017;2(2):e11200. [DOI:10.5812/jogcr.11200]
3. Aminimoghaddam S, Mohseni I, Afzalzadeh A, Esmaeeli S. Ovarian malignant mixed germ cell tumor: A case of unusual presentation as molar pregnancy. J Reprod Infertil. 2016;17(2):133-6.
4. DiSaia P, Creasman W, Mannel R, McMeekin DS, Mutch D. Clinical gynecologic oncology. 9th Edition. Amsterdam: Elsevier Health Sciences; 2017.
5. Rahmani M, Foroozi S, Akhavan S, Yarandi F, Aminimoghaddam S. OC27. 01: Role of imaging in assessment of gestational trophoblastic neoplasia and transvaginal Doppler ultrasound versus pelvic dynamic contrast enhanced MRI. Ultrasound Obstet Gynecol. 2016;48(S1):49-50.
6. Gary Cunningham F, Leveno J, Bloom L, Spong Y, Dashe S, Hoffman L, et al. Williams Obstetrics. 25th Edition. New York: McGraw-Hill Education; 2018.
7. Berek JS. Berek and Novak's gynecology. 15th Edition. Philadelphia: Lippincott Williams & Wilkins; 2011.
8. Aminimoghaddam S, Nezhadisalami F, Anjidani S, Tond SB. Outcome of treatment with EMA/EP (etoposide methotrexate and actinomycin-D/etoposide and cisplatin) regimen in gestational trophoblastic neoplasia. Med J Islam Repub Iran. 2018;32:36. [DOI:10.14196/mjiri.32.36] [PMID] [PMCID]
9. Aminimoghaddam S, Yarandi F, Nejadsalami F, Taftachi F. Human chorionic gonadotrophin as an indicator of persistent gestational trophoblastic neoplasia. Med J Islam Repub Iran. 2014;28:44. [DOI:10.1155/2014/494695] [PMID] [PMCID]
10. Stevens F, Katzorke N, Tempfer C, Kreimer U, Bizjak G, Fleisch M, et al. Gestational trophoblastic disorders: An update in 2015. Geburtshilfe Frauenheilkd. 2015;75(10):1043-50. [DOI:10.1055/s-0035-1558054] [PMID] [PMCID]
11. Ghaemmaghami F, Ashraf-Ganjooei T. Gestational trophoblastic neoplasia. Asia-Pacific J Clinic Oncol. 2006;2(1):9-21. [DOI:10.1111/j.1743-7563.2006.00035.x]
12. Yarandi F, Mousavi A, Abbaslu F, Aminimoghaddam S, Nekuie S, Adabi K, et al. Five-day intravascular methotrexate versus biweekly actinomycin-d in the treatment of low-risk gestational trophoblastic neoplasia: A clinical randomized trial. Int J Gynecol Cancer. 2016;26(5):971-6. [DOI:10.1097/IGC.0000000000000687] [PMID]
13. Rahimi Sharbaf F, Nekuie S, Mohseni M, Esmaili A, Khansari N, Moinfar Z, et al. Using ultrasound for diagnosing remnants of pregnancy after second-trimester abortion: is it practical?. Elixir Gynaecol. 2017;111:769-72.
14. Ashraf-Ganjooei T, Ghaemmaghami F. Patients with presenting unusual manifestations with gestational trophoblastic neoplasm: Case series and review of literatures. Arch Gynecol Obstet. 2008;277(5):465-70. [DOI:10.1007/s00404-007-0469-3] [PMID]
15. Ghaemmaghami F, Ashrafgangooei T, Gillani MM, Mosavi A, Behtash N. Major surgeries performed for gestational trophoblastic neoplasms in a teaching hospital in Tehran, Iran. J Gynecol Oncol. 2011;22(2):97-102. [DOI:10.3802/jgo.2011.22.2.97] [PMID] [PMCID]
16. Seckl M, Sebire N, Fisher R, Golfier F, Massuger L, Sessa C, et al. Gestational trophoblastic disease: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(suppl_6):vi39-vi50. [DOI:10.1093/annonc/mdt345] [PMID]
17. Fatemeh G, Shohreh B, Azamolsadat M, Tahereh A, Mitra MG, Nadereh B, et al. Assessment of the response to chemotherapy in gestational trophoblastic neoplasia with vaginal metastases. Arch Gynecol Obstet. 2008;278(4):315-8. [DOI:10.1007/s00404-008-0588-5] [PMID]
18. Jones HW, Rock JA. Telinde's operative gynecology. 11th Edition. Philadelphia: Lippincott Williams & Wilkins; 2015.
19. Farzaneh F, Vahedpour Z, Ashrafganjoei T, Rafizadeh M, Al e Bouyeh H, Hosseini M. Six-Month Follow-Up After Mole Evacuation. Obstet Gynecol cancer res. 2016;1(1):e7331. [DOI:10.17795/ojcr-7331]
| Rights and permissions | |
 |
Journal of Obstetrics, Gynecology and Cancer Research by Farname Inc is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. Based on a work at http://jogcr.com/. |
Copyright Policy
Journal of Obstetrics, Gynecology and Cancer Research by Farname Inc is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Based on a work at http://jogcr.com/.
